Mandy Lauw: Can Reduced-Dose DOACs Be Applied to All Patients With VTE?
Mandy Lauw, Internist-hematologist at Erasmus MC, shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:
“Evidence for the efficacy and safety of doac dose-reduction for extended VTE treatment is substantial with the renove, eve and api-cat trials. But does this apply to all patients?
This short narrative review in HemaSphere Journal, written together with Marc Carrier and Saskia Middeldorp, provides some relevant insights for clinicians whether reduced-dose doacs can be uniformly applied to all patients with thrombosis and an indication for long-term anticoagulation.”
Title: Extended treatment for venous thromboembolism: Is direct oral anticoagulant dose-reduction better for all?
Authors: Mandy N. Lauw, Saskia Middeldorp, Marc Carrier
Read the Full Article on HemaSphere Journal
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs